BASSEM SALTI ZEIDAN
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease NEW PORT RICHEY, FL NPI 1013571496
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease FL Janssen Pharmaceuticals, Inc All categories
General Payments — all program years on this page
$207.48
- Category: General Payments
- Program years: PY2023–2024
- Record count: 11
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $122.34 across 7 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $122.34 | 7 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Pharmaceuticals, Inc | $36.18 | 2 |
| Genentech USA, Inc. | $20.18 | 1 |
| Amgen Inc. | $19.79 | 1 |
| Mylan Specialty L.P. | $17.12 | 1 |
| ABBVIE INC. | $14.68 | 1 |
| Acerta Pharma LLC | $14.39 | 1 |
By program year
Records — PY2024 (7)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1077970858 | Janssen Pharmaceuticals, Inc | $18.30 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1077970878 | Janssen Pharmaceuticals, Inc | $17.88 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1105639060 | AstraZeneca Pharmaceuticals LP | $14.39 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1106392566 | ABBVIE INC. | $14.68 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1111746544 | Amgen Inc. | $19.79 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1132980839 | Genentech USA, Inc. | $20.18 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1147322910 | Mylan Specialty L.P. | $17.12 | 09/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.